ANAT ERDREICH-EPSTEIN, M.D., Ph.D.

ANAT ERDREICH-EPSTEIN, M.D., Ph.D.2018-11-26T07:44:57+00:00

Project Description

Dr. Anat Erdreich-Epstein

Dr. Anat Erdreich-Epstein
Translational Research Grant
– Medulloblastoma and Glioma

Children’s Hospital Los Angeles

chla-logo

Give to
Dr. Anat Erdreich-Epstein’s Research

Make a Donation

Dr. Anat Erdreich-Epstein is a physician-scientist and pediatric oncologist with a major laboratory research commitment. She seeks to understand the biology of brain tumors, now the most deadly form of pediatric cancer, in order to create new and better treatments against them. Her focus in this current research is to better understand the biology of medulloblastomas, the most common malignant brain tumors in children, in order to find new ways to approach its treatment.
Dr. Epstein and her lab team recently identified that levels of PID1, discovered only in 2006 and never before linked to cancer, are highly correlated with length of survival of children with medulloblastomas and adults with gliomas. She further found that PID1 has growth-inhibitory effects on brain tumor cells from three different types of brain tumors of children and adults: gliomas, medulloblastomas and atypical teratoid rhabdoid tumors (ATRT). Her team is currently working to understand the molecular mechanisms by which PID1 functions in cancer and in brain tumors in order to utilize this knowledge in the development of novel therapies.

With support from Pediatric Cancer Research Foundation, Dr. Epstein and her group will investigate the role of PID1 in the regulation of medulloblastoma growth. They hypothesize that PID1 affects the brain microenvironment in which the medulloblastoma tumors grow. They think this may be by suppressing the function of a tumor‐promoting protein that is well known in other cancers, but until now was not thought to have a role in medulloblastomas. This is important since there are effective drugs that target this protein which are already in use against other cancers.

Over the period of study, the group will determine the effect of PID1 on medulloblastoma microenvironment, the effect of PID1 on the function of this tumor‐promoting gene, and the effect of this tumor-promoting gene in medulloblastoma growth.
The results of this work will inform on critical aspects of medulloblastoma biology and may lead to novel approaches against the treatment of medulloblastoma and/or possibly repurposing of existing medicines for it. We are deeply grateful to Pediatric Cancer Research Foundation and its supporters for believing, as we do, that a cure for pediatric cancer is possible through the spark of scientific discovery.

[ Donate Now ]

CHANGE A LIFE TODAY

Some people say that children make up 10% of our cancer population, but they are 100% of our future! ~ Dr. Alex Huang, Case Western

VOLUNTEER
DONATE NOW